CD19是一种特异性表达于B淋巴细胞各个分化阶段的细胞表面抗原,绝大多数B系来源的恶性肿瘤包括B细胞急性淋巴细胞白血病、慢性淋巴细胞白血病和非霍奇金淋巴瘤细胞表达CD19。 因此它被认为是CAR-T治疗B细胞肿瘤的理想靶点。临床试验结果显示,CD19 CAR-T对急性B-淋巴细胞白血病(B-ALL)的治愈率已经达到了90%。 clinical...
产品名称: B Cell (CD19+) Total RNA, human .0 订购此产品 供应商: miltenyi 规格: 目录价: 4972.5 库存状态: CAS编号: 应用范围: 种属来源: 相关信息: 保存条件: 说明书地址: 点击查看详细 打印此页 关闭此页 上一个:Cytotoxic T Cell (CD8+) Total RNA, human[130-093-168/] 下一...
Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis. Clin. Immunol. 120, 106-120.Manske MK, Zuckerman NS, Timm MM, et al. Quantitative analysis of clonal bone marrow CD19+ B cells:...
As an exploratory analysis, we measured the frequencies of CD19-positive B cells in the PB of patients after CAR-NK cell treatment. At the time of enrollment, the majority of patients (31/37) had B cell lymphopenia (B cell count < 100 cells/μl) secondary to prior B cell-...
CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy. The high efficacy of CAR T cells in B-...
2020年9月21日,Cell期刊在线发表了斯坦福大学医学院科学家关于CAR-T疗法神经毒性来源的研究论文,通讯作者为Denis Migliorini和Ansuman T. Satpathy。CAR-T疗法先驱Carl June也参与了该工作。 研究人员利用单细胞技术鉴定出脑壁细胞(mural cells)表达CD19,可...
(new matrix), significantly shortening the culture time required to meet the dose, which is reflected by the increased total cell count by day 7 (P < 0.0001; Fig.2c) and decreased product doubling time (P = 0.04; Fig.2d). Among 39 patients who underwent apheresis, CAR T ...
Among the 12 patients, six had a low B cell count before lymphodepletion (< 50 cells/μL). All patients experienced B cell aplasia following lymphodepletion and AT101 infusion. Patient 8, who had progressive disease (PD) at 3 months, recovered B cells at the same time as the disease ...
CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, ...
Learn about BLINCYTO®, a treatment for CD19-positive MRD(+), R/R, and consolidation B-cell precursor ALL. See Full Safety Info, including Boxed Warning.